title: A combined approach to early detect in vitro drug-induced hemostatic changes in preclinical safety.
abstract: Early detection of drug-induced alterations of hemostasis is challenging. Drugs can affect different components of the Virchow's triad and measurement of plasmatic coagulation times lacks sensitivity. New techniques for a more global assessment of the hemostasis are now available: the impedance platelet aggregometry, the thromboelastography and the thrombin generation measurement. The aim of this study was to evaluate three techniques (i.e.: Multiplate®, TEG®and CAT) for the in vitro detection of the effect of a drug known to induce hemostatic alterations in a preclinical safety environment. Cyclosporine A was chosen and tested at 4 concentrations after solubilization in DMSO in Wistar rats and Beagle dogs. The results obtained were comparable between both species except for the thrombin generation in platelet rich plasma. Enhanced platelet aggregability was observed after ADP stimulation and alterations of the thromboelastograms consisted in decreased maximum amplitude and increased LY30. A dual effect on thrombin generation was observed and suggested that CsA may interact with platelets in rat platelet rich plasma and speed up thrombin generation. The results of this study indicate that using a combined approach on hemostasis testing in preclinical safety it is possible to detect in vitro drug-induced alterations of hemostasis.
authors.affiliation: PreClinical Safety, Discovery and Investigative Safety, Translational Immunology and Clinical Pathology, Novartis Institutes for BioMedical Research, Werk Klybeck, CH-4002 Basel, Switzerland. Electronic address: myriam.defontis@fr.citoxlab.com.
authors.forename: Myriam
authors.initials: M
authors.lastname: Defontis
authors.affiliation: PreClinical Safety, Discovery and Investigative Safety, Translational Immunology and Clinical Pathology, Novartis Institutes for BioMedical Research, Werk Klybeck, CH-4002 Basel, Switzerland.
authors.forename: Serge
authors.initials: S
authors.lastname: Côté
authors.affiliation: PreClinical Safety, Discovery and Investigative Safety, Translational Immunology and Clinical Pathology, Novartis Institutes for BioMedical Research, Werk Klybeck, CH-4002 Basel, Switzerland.
authors.forename: David
authors.initials: D
authors.lastname: Ledieu
mesh_terms: D000818:Animals; D001780:Blood Coagulation Tests / Q000379:methods*; D016572:Cyclosporine / Q000633:toxicity*; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000633:toxicity*; D008297:Male; D051381:Rats; D017208:Rats, Wistar
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine
keywords: Cyclosporin A; Hemostasis; Multiplate(®); Preclinical safety; TEG(®); Thrombin generation